Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Compass Pathways

This Psychedelic Drug Flopped on Trial Results. Should You Buy the Dip?

Compass Pathways took a 50% on June 23 hit after a lukewarm trial, but long-term bulls see upside in psychedelics.

Barchart

Compass Pathways Stock Is Plunging Today: What's Going On?

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial, but results may have not met lofty investor expectations.

Benzinga

Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.1% on Monday.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

1 Biotech Stock Under $10 That Could Surge 420%

Down 84% from all-time highs, Compass Pathways is a beaten-down biotech stock that trades at a massive discount to consensus price target estimates in 2024.

Barchart

World's largest trial into whether magic mushrooms can treat depression launched at London hospital

Scientists hail 'milestone' in mental health research as new site opens at Maudsley hospital in Camberwell

Evening Standard

Is the therapeutic potential of hallucinogens risky and overhyped?

As the medicinal use of psychedelics gains mainstream attention, fears remain over their effect on mental health and the need for safe administration

The Guardian - UK

Magic mushroom ingredient could help treat anorexia, research suggests

A single dose of the psychedelic, given alongside psychological support, is a safe and acceptable treatment for the condition, a study suggests

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Psilocybin may be a potential treatment for anorexia, research suggests

A single dose of the psychedelic, given alongside psychological support, is a safe and acceptable treatment for the condition, a study suggests.

The Independent UK

Magic mushrooms compound ‘effective at treating depression in cancer patients’

Largest ever trial of psilocybin offers hope of treatment to cancer patients with major depressive disorder

Evening Standard

Anorexia is the deadliest psychiatric disorder. Could psychedelics help?

A Nasdaq-listed company is trialling the active ingredient in magic mushrooms as a new treatment

Financial Times

A 36-year-old CEO saw how psychedelics treated his best friend’s mental illness. Now his Peter Thiel-funded firm wants to bring the drugs to the masses

Florian Brand's Atai Life Sciences went public three years after launching, fueled by Silicon Valley interest and promising science, but it's still waiting for its first big breakthrough.

Fortune

A single dose of psilocybin may alleviate major depression for 12 weeks, study finds

A psilocybin-based drug for treatment-resistant depression may be one step closer to approval, researchers say.

Inverse

COMPASS Pathways Shares Q3 2022 Financial Results, Business News & Term's Highlights

Psychedelics mental healthcare firm COMPASS Pathways (NASDAQ: CMPS) reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and business developments.

Benzinga

Magic mushrooms compound found to ‘significantly reduce’ depression symptoms in major trial

Psilocybin has been found to have a positive impact on patients suffering from treatment-resistant depression

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Magic-mushroom drug can reduce depression symptoms, study suggests

Psychedelic effects lasted between six to eight hours, and during this time a therapist was in the room to provide psychological support.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Upgrades

Benzinga

Compass Pathways Will Lead Two Concurrent Phase 3 Trials On Psilocybin-Assisted Therapy For Depression

Psychedelics biotech company Compass Pathways (NASDAQ: CMPS) announced it will conduct two separate Phase 3 clinical trials to study psilocybin-assisted therapy on Treatment-Resistant Depression (TRD),

Benzinga

Psychedelics Sector Poised To Soar If Compass Pathway's Chart Breaks This Pattern

Compass Pathways (NASDAQ: CMPS) has been trading relatively stronger than the S&P 500 recently, in a mostly sideways consolidation pattern compared to the market ETF, which entered into a steep downtrend on Aug. 16.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Psychedelics Management Updates: Two Top Companies Appoint New CEOs, Here's What We Know

Two companies in the psychedelics space have chosen new chief executive officers: COMPASS Pathways (NASDAQ: CMPS) has chosen Kabir Nath, and Small Pharma will be now led by George Tziras.

Benzinga

Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 6.63% at $0.71

Benzinga

US Senate Moves Forward On Gun Reform: 3 Stocks That Could Benefit As A Result

Tuesday night, the U.S. Senate finally cleared a procedural vote to move forward with gun control legislation. The action comes after weeks of negotiations.

Benzinga

Psychedelic Stock Gainers And Losers From June 14, 2022

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 9.90% at $9.44

Benzinga

ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 1.06% at $0.81 LOSERS:

Benzinga

Psychedelic Stock Gainers And Losers From May 12, 2022

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.44% at $7.06

Benzinga

Compass Pathways Reports Q1 Financial Results, With Increased R&D Expenses Compared To 2021

Compass Pathways (NASDAQ: CMPS) announced its financial results for the first quarter of 2022, which ended March 31. Q1 Results For the first three months of the year, net loss was $21.2 million, or $0.50 loss per share. For comparison, net loss in the same period of 2021 was $12.7 million…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

University of Edinburgh

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.